Oncotarget is an integrative conventional scientific and medical journal that provides free access to the most up-to-date academic and clinical research on cancer and experimental treatment analysis. The publication has become so popular among the medical industry and community, Oncotarget has expanded their subject materials to more than just oncology. The fields of study have now broadened to the areas of autophagy, cell destruction, cell cycle, immunology, microbiology, Chromosomes and gerotarget aging. Oncotarget publicizes the most relevant issues and findings every week so that noteworthy discoveries can be revealed without delay to its followers. The main objectives of Oncotarget’s Editors-in-Chief, Mikhail V. Blagosklonny and Andrei V. Gudkov, are included in the following list.
- To augment the influence of research data with insightful review
- To eliminate the boundaries between fields
- To bring together the various fields of biomedical science
- To encourage and advance the application of science and research to combat disease
- Assist all researchers in participating to the progress of science
- To foster ways to live without any diseases
- Freeing the study of oncology from any publication expenses
Oncotarget’s twenty contributing Editorial Board members have vast scientific expertise and backgrounds that belong to the National Academy of Sciences USA and are Nobel Prize and Lasker Award winners. They have published the works of some of the most respect researchers and authors in their fields including Andrew V. Schally, John Reed and Tony Hunter. The different kinds of articles Oncotarget reviews and publishes include commentaries, editorials, research findings, comprehensive reviews and books.
To get a better understanding of the subject matter Oncotarget provides, the titles of a couple of the latest published research papers is, “Next Generation Sequencing of Carcinoma of Unknown Primary Reveals Novel Combinatorial Strategies in a Heterogeneous Mutational Landscape” and “Multiple-Response Regression Analysis Links Magnetic Resonance Imaging Features to De-Regulated Protein Expression and Pathway Activity in Lower Grade Glioma.” Two of the current Editorials are titled, “Functional Proteomic Characterization of Cancer Cell Lines” and “Pharmacologic Targeting of Drug-Induced Enhancers.” Oncotarget is a valuable commodity toward the discovery of cures for cancer, other diseases and anti-aging breakthroughs.
With over twenty years of experience in oncology, Dr. Clay Siegall has been an integral and leading contributor to finding a cure for cancer. Dr. Siegall established Seattle Genetics, Inc. in 1997 and currently resides as its CEO. Seigall has an extensive scientific acumen in regard to therapeutic drug advancement. He also has authored over 67 scientific findings and is an editor for three distinguished scientific journals. He’s been awarded several notable awards and accolades including the “Pierce Award,” for his scientific work with toxins and “Ernst & Young Pacific Northwest Entrepreneur of the Year award.” Dr. Siegall has a Bachelor’s of Science in Zoology and a Doctorate of Philosophy in Genetics. Dr. Siegall is widely regarded among his constituents and the medical industry for his work with developing antibody based remedies including the drug Adcetris, which treats recurring systemic anaplastic lymphoma.
Seattle Genetics is valued at over $10 billion and has seen remarkable growth in not only marketing sales, but the number of employees it’s hired since inception. Employing over 900 workers, Seattle Genetics is the biggest bio-tech laboratory in the state of Washington. They have incredibly advanced therapeutic programs and antibody based drugs that have been developed to specifically target cancer cures and foster future patient outcome. They develop their antibody therapies by combining precise monoclonal antibodies, bonding agents and cogent cancer cell-destroying properties. They’re currently working on agents to target urothelial cancer, blood cancer and solid mass tumors. Seattle Genetics abides by a high degree of morality, patient empathy, innovative technology, leadership and excellence in scientific application. Some of the most genius minds in the scientific medical community are working to advance breakthroughs for cancer with Seattle Genetics. Dr. Siegall is among the foremost of those and has led remarkable advancement within the antibody-pharmaceutical therapies.
Dr. Siegall’s bio-tech company is expected to continue to vastly grow in the future as millions of dollars in funds have been allocated to purchase the universal rights to another promising cancer drug treatment. In two years, from 2014 to 2016, sales at Seattle Genetics had increased by 46% and over $400 million were accrued. Stocks catapulted from $20 a share to $66 a share through the middle of the year. This company has revolutionized cancer treatment therapy and given hope to thousands of people who suffer from the disease through the advancement of ADC and immune-oncology technology.